Our top pick for
Building a portfolio
CytoDyn Inc (CYDY) is a leading biotechnology business based in the US. It opened the day at USD$2.22 after a previous close of USD$2.13. During the day the price has varied from a low of USD$2.22 to a high of USD$2.9. The latest price was USD$2.82 (25 minute delay). CytoDyn is listed on the OTCQB and employs 19 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, CytoDyn's share price has had significant positive movement.
Its last close price was USD$2.82, which is 61.17% up on its pre-crash value of USD$1.095 and 256.96% up on the lowest point reached during the March crash when the shares fell as low as USD$0.79.
If you had bought USD$1,000 worth of CytoDyn shares at the start of February 2020, those shares would have been worth USD$642.58 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,861.40.
|52-week range||USD$0.911 - USD$10.01|
|50-day moving average||USD$4.2794|
|200-day moving average||USD$3.8318|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.188|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-04-09)||-9.90%|
|1 month (2021-03-17)||21.03%|
|3 months (2021-01-15)||-45.77%|
|6 months (2020-10-16)||0.36%|
|1 year (2020-04-17)||25.33%|
|2 years (2019-04-17)||526.67%|
|3 years (2018-04-17)||437.65%|
|5 years (2016-04-15)||138.98%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-77.37%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
We're not expecting CytoDyn to pay a dividend over the next 12 months.
Over the last 12 months, CytoDyn's shares have ranged in value from as little as $0.911 up to $10.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.4957. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.